Home › Bell Radar › LTGO

LTGOLatigo Biotherapeutics

US ExchangeHealth Care2026-08-07

Clinical-stage biotech developing non-opioid NaV1.8 inhibitors for acute and chronic pain indications.

$18IPO price

$346MRaised

$18.25Day-1 close

-7.22%Day-1 return

Clinical-stage biotech developing non-opioid NaV1.8 inhibitors for acute and chronic pain indications.

Company description (source: StockAnalysis)

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly k...

医疗健康

51CFO read: CFO must navigate pain therapy market access, alternative payment models, and pre-commercial finance planning.

Management details per the SEC prospectus.

Company profile SEC prospectus

Does your company need this kind of CFO?

51CFO matches you with Western CFOs who have each run a full US IPO — plus other C-level talent. First shortlist within 48 hours; free 30-minute listing-readiness read.

Talk to us